Skip to main content
. 2016 Sep 20;11:4799–4818. doi: 10.2147/IJN.S111736

Figure 5.

Figure 5

(A) %Hemolysis of blank LCNPs, AE-LCNPs (F6), and AE-PEGylated LCNPs with 1% w/v mPEG2KDSPE (F13) after 0.5-hour and 2-hour incubation period at 37°C. (B) Hemocompatibility profile of AE-PEGylated LCNPs with 2% w/v mPEG2KDSPE (a), AE-PEGylated LCNPs with 1% w/v mPEG2KDSPE (b), AE-PEGylated LCNPs with 0.5% w/v mPEG2KDSPE (c), AE-LCNPs (d) after 2-hour incubation period at 37°C. Changes in both PS (C) and PDI (D) of LCNP formulations after incubation in 10% FBS solution at 37°C.

Abbreviations: AE, aloe-emodin; FBS, fetal bovine serum; LCNPs, liquid crystalline nanoparticles; PDI, polydispersity index; PEG, polyethylene glycol; PS, particle size.